Glenmark Pharmaceuticals
| 200px | |
| Public company | |
| Traded as | BSE: 532296 NSE: GLENMARK) |
| Industry | Pharmaceuticals |
| Founded | 1977 |
| Founders | Gracias Saldanha |
| Headquarters | Mumbai, Maharashtra[1], India |
|
Area served
|
Global |
|
Key people
|
Glenn Saldanha, MD & CEO[2] |
| Products | Medicines and Vaccines |
| Revenue | ₹60.07 billion (US$890 million) (2009–2010)[3] |
|
Number of employees
|
11,500[4] |
| Subsidiaries | Glenmark Generics Ltd[5] |
| Website | www.glenmarkpharma.com |
Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India.[6] It manufactures and markets generic formulation products and active pharmaceutical ingredients (API), both in the domestic and international markets. In the formulation business, its business spans segments such as Dermatology, Internal Medicine, Paediatrics, Gynaecology, ENT and Diabetes.
It has four manufacturing facilities for formulations and additional three facilities for APIs. These manufacturing facilities are located in the states of Maharashtra, Goa, Himachal Pradesh and Gujarat in India.
It operates in 95 countries through its subsidiaries, Glenmark Pharmaceuticals USA, Glenmark Pharmaceuticals UK. Glenmark Pharmaceuticals SA.[7]
The formulations business has six manufacturing facilities, four in India and two overseas. These facilities are approved by several regulatory bodies. The facility at Baddi, Himachal Pradesh, India is also approved by MHRA and USFDA for semi-solids. The overseas facilities are situated in Brazil and the Czech Republic. While the manufacturing facility in Brazil services requirements of the Latin American region, the Czech facility services requirements of the Central Eastern Europe region. Glenmark has also invested in a dedicated R&D facility for formulations development. This R&D centre, situated near Nashik, India is engaged in developing specialty/ branded formulations for global markets.
Since getting listed on the stock exchange in 2000, when Glenmark registered revenue of USD 32 Mn, the company is currently ranked among the World's top 100 Pharma & Biotech companies. Recently, Glenmark has been chosen as the 'Best Company Across Emerging Markets' 2011, and recognized for the 'Best Overall Pipeline' 2011 by SCRIP, the largest selling and most respected pharmaceutical magazine in the world. SCRIP had also recognized Glenmark as 'Best Pharma Company in the World – SME' and 'Best Company in an Emerging Market' in 2008. Other awards and recognitions received by the company include the "Best under a Billion Dollar companies in Asia" for 2008 by Forbes, a leading international publication, "Indian Innovator Pharmaceutical Company of the Year - 2010" by Frost & Sullivan, and Gold Patent Award 2011 in the categories of API Formulations & Export of bulk drugs (Non Biologicals) by Pharmexcil.
References
- ↑ http://www.glenmarkpharma.com/UITemplate/HtmlContainer.aspx?res=P_GLN_CONTACT
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>
  |
This article about an Indian company is a stub. You can help Wikipedia by expanding it. |
